
|Videos|April 19, 2018
Dr. West on FDA Approval of Frontline Osimertinib in EGFR+ NSCLC
Author(s)H. Jack West, MD
H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the FDA approval of osimertinib (Tagrisso) in the frontline setting for patients with EGFR-mutation
Advertisement
H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the FDA approval of osimertinib (Tagrisso) in the frontline setting for patients with EGFR-mutation—positive non–small cell lung cancer (NSCLC).
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Unpacking the FDA Approvals That Reshaped Cancer Care in 2025
3
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
4
NCCN Guidelines Recognize MammaPrint/BluePrint for Determining Anthracycline Benefit in Breast Cancer
5



































